melanoma Clinical Trials and Research
Also known as: malignant melanoma, skin cancer, melanocytic tumor, cutaneous melanoma, ocular melanoma, mucosal melanoma · ICD-10: C43
Melanoma is a serious type of skin cancer that develops when pigment-producing cells grow out of control. Clinical trial research for melanoma often focuses on new immunotherapies, targeted therapies, and combination treatments to improve patient outcomes. Find a Trial helps patients search for active studies.
Common questions about melanoma clinical trials
What types of melanoma are being studied in clinical trials?
Clinical trials investigate various melanoma types, including cutaneous (skin), ocular (eye), and mucosal melanoma. Researchers are exploring treatments tailored to the genetic and molecular characteristics of each type, according to data from ClinicalTrials.gov.
What are common eligibility criteria for melanoma clinical trials?
Eligibility often depends on the trial's focus, but common criteria include the stage of melanoma, prior treatments received, and overall health status. Specific genetic markers or tumor characteristics may also be required, as seen on ClinicalTrials.gov.
What new treatments are being explored for melanoma?
Current research, as shown on ClinicalTrials.gov and NIH RePORTER, frequently investigates novel immunotherapies that boost the body's immune response, targeted therapies that block specific cancer growth pathways, and various combination approaches.
Do clinical trials for melanoma cost money?
Generally, the investigational treatment and study-related tests are covered by the trial sponsor. However, routine medical care costs, like doctor visits or hospital stays, are typically billed to the patient's insurance, as outlined in trial protocols.
What are the different phases of melanoma clinical trials?
Melanoma clinical trials progress through phases. Phase 1 assesses safety, Phase 2 evaluates effectiveness and side effects, and Phase 3 compares new treatments to standard care. Phase 4 monitors approved treatments long-term, as described by NIH.
Are there clinical trials for early-stage melanoma?
Yes, clinical trials for early-stage melanoma often focus on preventing recurrence after surgery, exploring new adjuvant therapies, or improving diagnostic methods. These studies aim to identify optimal strategies for long-term survival, according to ClinicalTrials.gov.
What biomarkers are important in melanoma research?
Key biomarkers in melanoma research include BRAF mutations, NRAS mutations, and PD-L1 expression, which can help predict response to targeted therapies and immunotherapies. Clinical trials often use these markers to stratify patients, as reported by NIH RePORTER.
What are common exclusion criteria in melanoma trials?
Common exclusion criteria might include certain autoimmune diseases, uncontrolled medical conditions, or prior severe reactions to similar investigational drugs. Pregnancy or breastfeeding are also typical exclusions to ensure patient safety, as detailed on ClinicalTrials.gov.
How to find a melanoma trial that fits you
- Describe your melanoma situation in detail — stage if applicable, prior treatments, age, and other relevant conditions.
- Use the location filter (worldwide, US, US & Canada, Europe) to narrow to trials near you.
- Review each trial's eligibility criteria carefully. Save 2–5 candidates with their NCT numbers.
- Discuss with your treating clinician before contacting the research site.